Abstract:Therapeutically actionable ROS1 rearrangements have been described in 1-3% of non-small cell lung cancer (NSCLC). Screening for ROS1 rearrangements is recommended to be by immunohistochemistry (IHC), followed by confirmation with fluorescence in situ hybridisation (FISH) or sequencing. However, in practise ROS1 IHC presents difficulties due to conflicting scoring systems, multiple clones and expression in tumours that are wild-type for ROS1. We assessed ROS1 IHC in 285 consecutive cases of NSCLC with non-squamous histology over a nearly 2-year period. IHC was scored with ROS1 clone D4D6 (n=270), clone SP384 (n=275) or both clones (n=260). Results were correlated with ROS1 break-apart FISH (n=67), ALK status (n=194), and sequence data of EGFR (n=178) and other drivers, where possible. ROS1 expression was detected in 161/285 cases (56.5%), including 13/14 ROS1 FISH-positive cases. There was no ROS1 expression in one ROS1 FISH-positive case in which sequencing detected an ALK-EML4 fusion, but not a ROS1 fusion. The other 13 ROS1 FISH-positive cases showed moderate to strong staining with both IHC clones. However, one case with a TPM3-ROS1 fusion would have been scored as negative with SP384 and D4D6 clones by some previous criteria. ROS1 expression was also detected in 58/285 cases (20.4%) that had driver mutations in genes other than ROS1. A sensitivity of 100% for detecting a ROS1 rearrangement by FISH was achieved by omitting intensity from the IHC scoring criteria and expression in >0% cells with D4D6 or in ≥50% cells with SP384. Excluding cases with driver events in any MAPK pathway gene (e.g., in ALK, EGFR, KRAS, BRAF, ERBB2 and MET) substantially reduced the number of cases proceeding to ROS1 FISH. Only 15.9% of MAPK-negative NSCLC would proceed to FISH for an IHC threshold of >0% cells with D4D6, with a specificity of 42.4%. For a threshold of ≥50% cells with SP384, only 18.5% of MAPK-negative cases would proceed to FISH, with a specificity of 31.4%. Based on our data we suggest an algorithm for screening for ROS1 rearrangements in NSCLC in which ROS1 FISH is only performed in cases that have been demonstrated to lack activating mutations in any MAPK pathway gene by comprehensive sequencing and ALK IHC, and show staining at any intensity in ≥50% of cells with clone SP384, or >0% cells with D4D6.

A Genomic And Clinicopathological Study Of Non-Small-Cell Lung Cancers With Discordant Ros1 Gene Status By Fluorescence In-Situ Hybridisation And Immunohistochemical Analysis

[Clinical Features of 54 Cases of Lung Adenocarcinomas with C-Ros Oncogene 1 Fusion].

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas Based on Histologic Features.

Advanced Lung Adenocarcinomas with ROS1-rearrangement Frequently Show Hepatoid Cell

ROS1 Fusions in Chinese Patients with Non-Small-cell Lung Cancer.

High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer.

Screening of Nsclc Samples from Chinese Lung Cancer Patients for Activating Rearrangements of the Alk, Ret, and Ros1 Genes.

PUB106 Different ALK/ROS1 Variants in Prognosis of Surgical NSCLC Patients

Detection of Lung Adenocarcinoma with ROS1 Rearrangement by IHC, FISH, and RT-PCR and Analysis of Its Clinicopathologic Features.

ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance

Clinicopathologic Characteristics of Patients with ROS1 Fusion Gene in Non-Small Cell Lung Cancer: a Meta-Analysis.

Lung Cancer with Concurrent EGFR Mutation and ROS1 Rearrangement: a Case Report and Review of the Literature

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma

Ros1 Rearrangements Define A Unique Molecular Class of Lung Cancers

Clinicopathological Characteristics and Outcomes of ROS1-rearranged Patients with Lung Adenocarcinoma Without EGFR, KRAS Mutations and ALK Rearrangements.

Concurrent Classic Driver Oncogenes Mutation with ROS1 Rearrangement Predicts Superior Clinical Outcome in NSCLC Patients.

Detecting Alk, Ros1 and Ret Fusion Genes in Cell Block Samples

P3.02-026 the Study of ROS1 Rearrangement in Advanced Primary Non-Small Cell Lung Cancer and Associated Metastatic Lesions

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF